TMFUltraLong

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and investment planning. You'll often find him writing about Obamacare, marijuana, drug and device development, Social Security, taxes, retirement issues and general macroeconomic topics of interest.

TMFUltraLong’s Activity

Yesterday

NL

Article

TMFUltraLong published an article 12:00 AM

A Short Squeeze and the Rumor Mill Stir Up Agios Pharmaceuticals, Inc. in April

Shareholders relish in Agios' 21% spike in April, but can the momentum continue?

Wed May 4

NL

Article

TMFUltraLong published an article 12:00 AM

3 Cheap Growth Stocks You Can Buy Right Now

These three growth stocks are cheap now, but they might not stay cheap for much longer.

NL

Article

TMFUltraLong published an article 12:00 AM

Gold and Silver Miners Suffer a Meltdown, but It's Not Time to Panic

Profit-taking crushes gold and silver stocks, but the fundamental picture still looks mostly lustrous.

Tue May 3

NL

Article

TMFUltraLong published an article 12:00 AM

1 Minor Blight Aside, Pfizer's Q1 Results Blew the Lid Off Wall Street's Expectations

Pfizer's quarter pretty much couldn't have gone any better, and it has a few key franchises to thank for its superior performance.

NL

Article

TMFUltraLong published an article 12:00 AM

The Possible Reason Behind Organovo Holdings, Inc.'s Big Climb in April

Organovo's pop last month is really a "short" story.

NL

Article

TMFUltraLong published an article 12:00 AM

1 Big Reason Why Inovio Pharmaceuticals, Inc. Was All the Buzz in April

While the world watched in disbelief as the Zika virus spread, Inovio's valuation continued to climb.

NL

Article

TMFUltraLong published an article 12:00 AM

Intrexon Corporation Shares Were Stung in April -- Here's Why

Intrexon became the buzz of Wall Street for all the wrong reasons in April.

NL

Article

TMFUltraLong published an article 12:00 AM

2 Big Reasons Why Shares of Exelixis, Inc. Soared 15% in April

Exelixis' revenue channels are widening, and Wall Street is taking notice.

NL

Article

TMFUltraLong published an article 12:00 AM

Allergan PLC Shares Shed 19% in April After Being Blindsided by the U.S. Treasury

A flurry of new tax inversion regulations crushes Allergan's intentions of merging with pharmaceutical giant Pfizer -- but not all hope is lost for Allergan or its shareholders.

NL

Article

TMFUltraLong published an article 12:00 AM

3 Attractive Income Stocks Whose Dividends Could Double

Want bigger dividend payouts? These three stocks may soon oblige.

NL

Article

TMFUltraLong published an article 12:00 AM

Here's Why Jazz Pharmaceuticals PLC Was on the Receiving End of a 15% Boost in April

These two catalysts -- one far more important than the other -- provided the sparks for Jazz last month.

NL

Article

TMFUltraLong published an article 12:00 AM

Valeant Pharmaceuticals Intl. Inc. Jumped 27% in April, But It's Not Out of the Woods

A few things finally go right in April for Valeant, but that doesn't mean the tide has turned.

Mon May 2

NL

Article

TMFUltraLong published an article 12:00 AM

5 Data Points Wall Street Is Anxiously Awaiting in Merck's Q1 Report

Slated to report its first-quarter results Thursday morning, here are the numbers you'll want to pay the closest attention to.

NL

Article

TMFUltraLong published an article 12:00 AM

This New Stock Market Trend Is Catching Investors By Surprise (but It Shouldn't)

This type of safe-haven investment has been turned upside down recently, but that's little cause of concern for long-term investors.

NL

Article

TMFUltraLong published an article 12:00 AM

Pacira Pharmaceuticals Inc.'s Double-Digit Drop Explained

One figure in Pacira's first-quarter earnings report is worrying Wall Street.

NL

Article

TMFUltraLong published an article 12:00 AM

7 Things on Investors' Minds Heading Into Pfizer's Q1 Report Tomorrow

There's much more to Pfizer's Q1 earnings report than whether the company can meet or beat its EPS and sales expectations. Here are seven points you should pay close attention to.

Fri Apr 29

NL

Article

TMFUltraLong published an article 12:00 AM

Why Great Panther Silver Ltd. Is Looking Lustrous

A big rally in precious metals gives Great Panther a lift, but there's much more going on behind the scenes.

Thu Apr 28

NL

Article

TMFUltraLong published an article 12:00 AM

Aside From 1 Eyesore, Amgen Delivers Another Solid Quarter

Despite disappointment surrounding its next-generation injectable drug, Amgen's Q1 offered plenty of evidence that its long-term growth strategy is on track.

NL

Article

TMFUltraLong published an article 12:00 AM

Celgene's Mixed Guidance Is No Reason to Panic

Celgene's forward guidance proves it's fallible, but that's nothing for investors to fear.

NL

Article

TMFUltraLong published an article 12:00 AM

The Single Most Important Thing About GlaxoSmithKline's Q1 Report

Forget that GSK handily topped Wall Street's sales and EPS estimates -- this is far more important.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 99.89
Player Rank 87 out of 74852
Score 9052.72
Score Change Today -11.63
Accuracy 88.53%
Active Picks 98
Total Picks 506
Best Pick FAZ (+306.43)
Worst Pick PCYC.DL (-8878.78)
Average Score per Pick 18.03
Charms Earned 16
Highest Rated Favorite TMFBabo
Go to TMFUltraLong’s CAPS page

Boards Stats & Trivia

CAPS All Star
Board Posts 3
Recs Received 11
People who have rec'd these posts 11
Recs to Posts Ratio (last 30 days) N/A
Threads Started 2
Threads Started Percentage 66.67 %
Most Frequent Board CAPS Feedback
Very First Post Tickering....Just a heads up... (10/14/2010)
Percentage of Posts Rec'd 100.00 %
Show TMFUltraLong’s 10 Latest Posts